A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
ImmunityBio, Inc.
AbbVie
BioNTech SE
OncoC4, Inc.
Tianjin Medical University Cancer Institute and Hospital
Bristol-Myers Squibb
Akeso
Alliance for Clinical Trials in Oncology
Gustave Roussy, Cancer Campus, Grand Paris
OSE Immunotherapeutics
Merck Sharp & Dohme LLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
AstraZeneca
Gilead Sciences
BioNTech SE
Revolution Medicines, Inc.
Second Xiangya Hospital of Central South University
CatalYm GmbH
Merck Sharp & Dohme LLC
University Medical Center Groningen
Kyowa Kirin Co., Ltd.
SWOG Cancer Research Network
Oscotec Inc.
University of Illinois at Chicago
STCube, Inc.
Maia Biotechnology
Tianjin Medical University Cancer Institute and Hospital
Intergroupe Francophone de Cancerologie Thoracique
Krystal Biotech, Inc.
Weill Medical College of Cornell University
Genelux Corporation
Memgen, Inc.
Dizal Pharmaceuticals
Hospital Sultanah Bahiyah
The First Affiliated Hospital of Xiamen University
Fox Chase Cancer Center
Phanes Therapeutics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China
Henan Cancer Hospital
Beijing Chest Hospital, Capital Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Shanghai Jiao Tong University School of Medicine
The First Affiliated Hospital of Guangzhou Medical University